Efficacy and safety of CT-P39, an omalizumab biosimilar, in chronic spontaneous urticaria: 16-week follow-up study.

Grattan C, Dytyatkovska Y, Springer M, Ratkova M, Krusheva B, Krupa-Borek I, Pulka G, Chełmińska M, Reich A, Kim S, Bae Y, Kim S, Lee S, An E, Park JE, Ka J, Kim J, Saini SS

Open source

DOI: 10.1002/clt2.70069
Published: 2025 Jun
Container: Clinical and translational allergy
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/clt2.70069,
  title = {Efficacy and safety of CT-P39, an omalizumab biosimilar, in chronic spontaneous urticaria: 16-week follow-up study.},
  author = {Grattan C and Dytyatkovska Y and Springer M and Ratkova M and Krusheva B and Krupa-Borek I and Pulka G and Chełmińska M and Reich A and Kim S and Bae Y and Kim S and Lee S and An E and Park JE and Ka J and Kim J and Saini SS},
  year = {2025},
  journal = {Clinical and translational allergy},
  doi = {10.1002/clt2.70069},
  url = {https://doi.org/10.1002/clt2.70069}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of CT-P39, an omalizumab biosimilar, in chronic spontaneous urticaria: 16-week follow-up study.
AU  - Grattan C
AU  - Dytyatkovska Y
AU  - Springer M
AU  - Ratkova M
AU  - Krusheva B
AU  - Krupa-Borek I
AU  - Pulka G
AU  - Chełmińska M
AU  - Reich A
AU  - Kim S
AU  - Bae Y
AU  - Kim S
AU  - Lee S
AU  - An E
AU  - Park JE
AU  - Ka J
AU  - Kim J
AU  - Saini SS
PY  - 2025
JO  - Clinical and translational allergy
DO  - 10.1002/clt2.70069
UR  - https://doi.org/10.1002/clt2.70069
ER  -

APA

C, G., Y, D., M, S., M, R., B, K., I, K., G, P., M, C., A, R., S, K., Y, B., S, K., S, L., E, A., JE, P., J, K., J, K., & SS, S. (2025). Efficacy and safety of CT-P39, an omalizumab biosimilar, in chronic spontaneous urticaria: 16-week follow-up study.. Clinical and translational allergy. https://doi.org/10.1002/clt2.70069

Source records

pubmed · retrieved 2026-09-26T23:14:48.071Z